ATE397934T1 - Biologisch abbaubare intraokulare implantate mit prostamiden - Google Patents

Biologisch abbaubare intraokulare implantate mit prostamiden

Info

Publication number
ATE397934T1
ATE397934T1 AT05740976T AT05740976T ATE397934T1 AT E397934 T1 ATE397934 T1 AT E397934T1 AT 05740976 T AT05740976 T AT 05740976T AT 05740976 T AT05740976 T AT 05740976T AT E397934 T1 ATE397934 T1 AT E397934T1
Authority
AT
Austria
Prior art keywords
prostamids
intraocular implants
biodegradable intraocular
biodegradable
relates
Prior art date
Application number
AT05740976T
Other languages
English (en)
Inventor
Patrick Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE397934T1 publication Critical patent/ATE397934T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05740976T 2004-04-30 2005-04-20 Biologisch abbaubare intraokulare implantate mit prostamiden ATE397934T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/837,260 US7799336B2 (en) 2004-04-30 2004-04-30 Hypotensive lipid-containing biodegradable intraocular implants and related methods

Publications (1)

Publication Number Publication Date
ATE397934T1 true ATE397934T1 (de) 2008-07-15

Family

ID=34977040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05740976T ATE397934T1 (de) 2004-04-30 2005-04-20 Biologisch abbaubare intraokulare implantate mit prostamiden

Country Status (14)

Country Link
US (11) US7799336B2 (de)
EP (2) EP1944032B1 (de)
JP (3) JP5576018B2 (de)
KR (1) KR101117904B1 (de)
CN (2) CN104288155A (de)
AT (1) ATE397934T1 (de)
AU (1) AU2005244203B2 (de)
BR (1) BRPI0510311B8 (de)
CA (1) CA2565053C (de)
DE (1) DE602005007478D1 (de)
DK (2) DK1944032T3 (de)
ES (2) ES2304701T3 (de)
NZ (1) NZ549516A (de)
WO (1) WO2005110424A1 (de)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
EP1339438B1 (de) * 2000-11-29 2005-10-19 Allergan Inc. Verhinderung von transplantatabstossung im auge
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20070027164A1 (en) * 2003-01-29 2007-02-01 Stockwell Brent R Agents for treating neurodegenerative diseases
US20070078144A1 (en) * 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US20070161644A1 (en) * 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
DE602006005826D1 (de) * 2005-09-21 2009-04-30 Univ Aston Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
SG170816A1 (en) 2006-03-31 2011-05-30 Qlt Plug Delivery Inc Drug delivery methods, structures, and compositions for nasolacrimal system
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
WO2007149476A2 (en) * 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Assays for non-apoptotic cell death and uses thereof
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
AU2013213742B2 (en) * 2006-12-19 2016-05-12 Allergan, Inc. Processes for making cyclic lipid implants for intraocular use
AU2016213848A1 (en) * 2006-12-19 2016-09-01 Allergan, Inc. Processes for making cyclic lipid implants for intraocular use
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8968396B2 (en) 2007-07-23 2015-03-03 Powervision, Inc. Intraocular lens delivery systems and methods of use
US20090082862A1 (en) * 2007-09-24 2009-03-26 Schieber Andrew T Ocular Implant Architectures
CN103932840B (zh) * 2007-09-24 2017-04-12 伊万提斯公司 眼部植入物及方法
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8734377B2 (en) * 2007-09-24 2014-05-27 Ivantis, Inc. Ocular implants with asymmetric flexibility
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
US8808222B2 (en) 2007-11-20 2014-08-19 Ivantis, Inc. Methods and apparatus for delivering ocular implants into the eye
US8512404B2 (en) 2007-11-20 2013-08-20 Ivantis, Inc. Ocular implant delivery system and method
AU2009221859B2 (en) 2008-03-05 2013-04-18 Alcon Inc. Methods and apparatus for treating glaucoma
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2296621A1 (de) * 2008-05-20 2011-03-23 Yale University Ein hydrophobes arzneimittel umfassende biologisch abbaubare polymer-mikroteilchen mit verzögerter freisetzung zur ophthalmischen anwendung
EP2303184A4 (de) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc Kombinationsbehandlung von grünem star
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
US20100098772A1 (en) * 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
WO2010065970A1 (en) 2008-12-05 2010-06-10 Ivantis, Inc. Methods and apparatus for delivering ocular implants into the eye
US8034363B2 (en) * 2008-12-11 2011-10-11 Advanced Technologies And Regenerative Medicine, Llc. Sustained release systems of ascorbic acid phosphate
EP2389221B1 (de) * 2009-01-23 2023-08-16 Mati Therapeutics Inc. Verzögerte freigesetzte lieferung von einem oder mehr wirkstoffen
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (de) 2009-05-18 2018-01-10 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
EP2437684B1 (de) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Wirkstofffreisetzung im vorderen augensegment
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
JP5635605B2 (ja) 2009-07-09 2014-12-03 イバンティス インコーポレイテッド 眼内インプラント及び眼内インプラントを眼球内に送出するための方法
US9693899B2 (en) 2009-07-09 2017-07-04 Ivantis, Inc. Single operator device for delivering an ocular implant
JP2013508096A (ja) 2009-10-23 2013-03-07 イバンティス インコーポレイテッド 眼内移植システムおよび眼内移植方法
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
JP6182313B2 (ja) 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法
CA2795706A1 (en) * 2010-04-06 2011-10-13 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
EP2571526B1 (de) * 2010-05-17 2019-03-13 Novaer Holdings, Inc. Wirkstofffreisetzungsvorrichtungen zur freisetzung okularer therapeutischer wirkstoffe
US8545430B2 (en) 2010-06-09 2013-10-01 Transcend Medical, Inc. Expandable ocular devices
WO2011159824A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
US9510973B2 (en) 2010-06-23 2016-12-06 Ivantis, Inc. Ocular implants deployed in schlemm's canal of the eye
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
EP2654715B1 (de) 2010-11-24 2017-01-25 Dose Medical Corporation Arzneimittelfreisetzendes augenimplantat
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
EP3378480A1 (de) * 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung des stoffwechselsyndroms
AU2012217630A1 (en) 2011-02-17 2013-09-05 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (de) 2011-02-23 2014-01-01 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
JP5989780B2 (ja) 2011-09-14 2016-09-07 フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． 眼挿入装置および方法
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (de) 2012-02-16 2016-11-02 Allergan, Inc. Zusammensetzungen und verbesserte verfahren für den ersatz von weichgewebe
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
EP3530268B1 (de) 2012-10-09 2021-12-15 Attentive Therapeutics, Inc. Therapeutische behandlung
US20140105956A1 (en) * 2012-10-11 2014-04-17 Rupak BANERJEE Biodegradable polymer based microimplant for ocular drug delivery
US9539240B2 (en) 2012-10-24 2017-01-10 Biocopea Limited Drug combinations and methods for reducing or maintaining cholesterol or HDL/LDL levels
RU2652063C2 (ru) 2012-10-26 2018-04-24 Форсайт Вижн5, Инк. Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
WO2014085450A1 (en) 2012-11-28 2014-06-05 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
JP6513576B2 (ja) 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
EP2956096A1 (de) 2013-02-15 2015-12-23 Allergan, Inc. Implantat mit langzeit-wirkstofffreisetzung
EP2967842B1 (de) 2013-03-15 2020-11-04 Alcon Inc. Verfahren zum rekonfigurieren einer intraokularlinse zur abgabe an eine abgabevorrichtung
WO2014143754A2 (en) * 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (de) * 2013-03-27 2016-02-03 Forsight Vision5, Inc. Okulare bimatoprost-silikoneinsätze und verfahren zur verwendung davon
AU2014248460B2 (en) * 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
PT3062775T (pt) 2013-10-31 2018-03-06 Allergan Inc Implantes intraoculares contendo prostamida e métodos para a sua utilização
EP3110375B1 (de) 2014-02-26 2022-01-26 Allergan, Inc. Vorrichtung zum einsetzen von intraokularimplantaten
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US20160008376A1 (en) 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
WO2016011056A1 (en) 2014-07-14 2016-01-21 Ivantis, Inc. Ocular implant delivery system and method
JP6847848B2 (ja) 2014-12-15 2021-03-24 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤、及び緑内障の治療におけるその使用方法
US10434071B2 (en) * 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP4265231A3 (de) 2015-08-14 2023-12-20 Alcon Inc. Augenimplantat mit drucksensor
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
CN116077626A (zh) 2015-10-31 2023-05-09 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
HK1257499A1 (zh) 2015-11-12 2019-10-25 Graybug Vision, Inc. 用於治疗的聚集性微粒
US11938058B2 (en) 2015-12-15 2024-03-26 Alcon Inc. Ocular implant and delivery system
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
KR102605349B1 (ko) 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
AU2017252294B2 (en) 2016-04-20 2021-12-02 Glaukos Corporation Bioresorbable ocular drug delivery device
DE102016207548A1 (de) 2016-05-02 2017-11-02 Tesa Se Härtbare Klebemasse und darauf basierende Reaktivklebebänder
DE102016207540A1 (de) 2016-05-02 2017-11-02 Tesa Se Wasserdampfsperrende Klebemasse mit hochfunktionalisiertem Poly(meth)acrylat
CN114532976A (zh) 2016-05-31 2022-05-27 酷拉公司 可植入眼压传感器和使用方法
EP4046609B1 (de) 2016-09-30 2025-02-26 Mati Therapeutics Inc. Augenmedikation mit verzögerter freisetzung und verwendung davon
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US20190192341A1 (en) 2017-11-09 2019-06-27 Allergan, Inc. Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect
EP3755287B1 (de) 2018-02-22 2024-04-03 Alcon Inc. Augenimplantat
KR102191180B1 (ko) * 2019-05-31 2020-12-15 삼진제약주식회사 안질환 치료용 조성물
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2020302924A1 (en) 2019-06-27 2022-02-17 Layerbio, Inc. Ocular device delivery methods and systems
CN110152120A (zh) * 2019-07-02 2019-08-23 北京林特医药科技有限公司 一种外c提升注射方法
PT3861985T (pt) 2020-02-06 2023-08-03 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
EP4142664A4 (de) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. Verfahren zur behandlung von allergischer konjunktivitis
US20230226138A1 (en) 2020-06-01 2023-07-20 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
EP3936113A1 (de) * 2020-07-07 2022-01-12 Occlugel Hydrophile, abbaubare mikrokugel zur abgabe von travoprost
TW202216159A (zh) * 2020-07-21 2022-05-01 美商歐樂根公司 具高負載前列腺素醯胺之眼內植入物
CN112451513A (zh) * 2020-11-02 2021-03-09 杭州利孚泰生物科技有限公司 丹酚酸a在制备防治可见光性视网膜损伤药物中的用途
CA3202776A1 (en) 2021-01-11 2022-07-14 Wayne A. Noda Systems and methods for viscoelastic delivery
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1040561A (en) * 1961-08-23 1966-09-01 Hosiery And Allied Trades Res Improvements in the production of crimped yarns
AT252264B (de) 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (sv) 1974-02-18 1976-12-13 N G Y Torphammar Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966749A (en) 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4396625A (en) 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4693885A (en) 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4675338A (en) 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
FR2577509B1 (fr) 1985-02-21 1987-05-07 Nirvana Espar Systems Sa Mat de bateau a voile
US4656186A (en) 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
DE3734223A1 (de) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4813261A (en) 1988-03-02 1989-03-21 Huck Manufacturing Company Rotatable offset nose assembly for setting fasteners
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
WO1990002553A1 (en) 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4932984A (en) 1989-07-27 1990-06-12 The Dow Chemical Company Process for reduction of chlorinated solvent emissions
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5100431A (en) 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2055522A1 (en) * 1990-12-12 1992-06-13 Masako Andoh Microspheres for ophthalmic use
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
DE69213739T2 (de) 1991-06-21 1997-02-20 Genetics Institute, Inc., Cambridge, Mass. Osteogene proteine enthaltende arzneimittel
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
IT1263116B (it) 1992-04-09 1996-07-30 Rotta Research Lab Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
US5655832A (en) 1992-04-16 1997-08-12 Tir Technologies, Inc. Multiple wavelength light processor
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
AU1042495A (en) * 1993-12-08 1995-06-27 Vitaphore Corporation Microsphere drug delivery system
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5523301A (en) 1994-08-05 1996-06-04 Merck & Co., Inc. Optic nerve health
US6270492B1 (en) 1994-09-09 2001-08-07 Cardiofocus, Inc. Phototherapeutic apparatus with diffusive tip assembly
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
MX9700850A (es) 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5612364A (en) 1995-11-08 1997-03-18 Alcon Laboratories, Inc. Substantially pure apraclonidine
WO1997026869A1 (en) 1996-01-24 1997-07-31 United States Government Represented By The Secretary Of The Army Novel 'burst-free' sustained release poly-(lactide/glycolide) microspheres
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
WO1998010758A1 (en) 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US6034413A (en) * 1997-02-27 2000-03-07 Texas Instruments Incorporated High speed biCMOS gate power for power MOSFETs incorporating improved injection immunity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
AU727080B2 (en) 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
JP2001513369A (ja) 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
US6054576A (en) * 1997-10-02 2000-04-25 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6271220B1 (en) 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
AU4645099A (en) 1998-07-09 2000-02-01 Yoram Harth Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea
JP2002521332A (ja) 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
AU5114499A (en) * 1998-07-21 2000-02-14 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
ATE269114T1 (de) 1998-11-20 2004-07-15 Univ Connecticut Verfahren und vorrichtung zur steuerung der gewebeimplantat-interaktionen
US6356629B1 (en) * 1999-02-02 2002-03-12 Cisco Technology, Inc. Switched virtual circuit controller setup congestion management strategy
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
US6290713B1 (en) 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
JP3584441B2 (ja) * 1999-08-26 2004-11-04 本田技研工業株式会社 ロックアップ機構付きトルクコンバータ
US6317616B1 (en) 1999-09-15 2001-11-13 Neil David Glossop Method and system to facilitate image guided surgery
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6319273B1 (en) 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
WO2001058240A2 (en) 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6385887B1 (en) * 2000-06-07 2002-05-14 Kenneth E. Johnston Muzzle loading firearm and adaptor
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
IL151530A0 (en) 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
DK1305057T3 (da) * 2000-07-31 2005-10-24 Iscience Corp Mikropartikelformig biomaterialesammensætning af hyaluronsyre til medicinsk anvendelse
US6855154B2 (en) * 2000-08-11 2005-02-15 University Of Louisville Research Foundation, Inc. Endovascular aneurysm treatment device and method
US6357568B1 (en) 2000-09-27 2002-03-19 Shou Mao Chen Structure for protecting a luggage shell
WO2002058730A2 (en) 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
EP1339438B1 (de) * 2000-11-29 2005-10-19 Allergan Inc. Verhinderung von transplantatabstossung im auge
US6595945B2 (en) 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
CA2443937A1 (en) * 2001-04-23 2002-10-31 Randall D. Glickman Prostanoids augment ocular drug penetration
EP1387671A1 (de) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantierbare arzneistoffverabreichungsvorrichtung und verwendung derselben
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
JP2005507866A (ja) 2001-08-07 2005-03-24 ヴィスタ サイエンティフィック エルエルシー 管理治療のための薬物放出システム
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20030220376A1 (en) 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
WO2003020172A1 (en) 2001-08-29 2003-03-13 De Carvalho Ricardo A P An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
CA2466757A1 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
US20040029771A1 (en) 2002-02-28 2004-02-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2003092665A2 (en) 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
DE60334905D1 (de) 2002-06-06 2010-12-23 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
CA2495917A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
JP4482726B2 (ja) * 2002-08-29 2010-06-16 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
RU2355385C2 (ru) 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
JP2004196787A (ja) 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050003007A1 (en) 2003-07-02 2005-01-06 Michele Boix Method of sterilization of polymeric microparticles
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
EP1711186A4 (de) 2004-02-04 2009-03-18 Retmed Pty Ltd Langsam freigesetzte steroidzusammensetzung
ITMI20040307A1 (it) 2004-02-24 2004-05-24 Iveco Spa Miglioramenti a un ponte a bracci piantati per veicoli
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244466A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7589057B2 (en) * 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244461A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244478A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244465A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244462A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
AU2005240078A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050282902A1 (en) 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7101904B2 (en) 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US7101906B2 (en) 2004-11-16 2006-09-05 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7183324B2 (en) 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
BRPI0605926A2 (pt) 2005-01-14 2009-05-26 Allergan Inc ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
EP1856042B1 (de) 2005-03-10 2012-06-27 Allergan, Inc. Substituierte gammalactame als therapeutika
ATE515263T1 (de) 2005-05-06 2011-07-15 Allergan Inc Substituierte beta-lactame und deren verwendung in der medizin
WO2007005176A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US20070015838A1 (en) 2005-07-14 2007-01-18 Allergan, Inc. Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
CA2850858A1 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
WO2007056087A1 (en) 2005-11-03 2007-05-18 Allergan, Inc. Prostaglandins and analogues as agents for lowering intraocular pressure
US7585895B2 (en) 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
CN101330914A (zh) 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
EP1978892B1 (de) 2006-01-17 2017-11-15 Novartis Ag Behandlungsvorrichtung zur wirkstofffreisetzung
US7592364B2 (en) 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
PE20080142A1 (es) 2006-03-15 2008-04-14 Boehringer Ingelheim Int Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion
EP1996546B1 (de) 2006-03-20 2014-11-26 Allergan, Inc. Substituierte gamma-lactame als prostaglandin-ep4-agonisten
US7439372B2 (en) 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
US7491844B2 (en) 2006-05-04 2009-02-17 Allergan, Inc. Therapeutic cyclopentane derivatives
US20070293873A1 (en) 2006-06-19 2007-12-20 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20070298073A1 (en) 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US7947732B2 (en) 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
US7999040B2 (en) 2007-09-25 2011-08-16 Nanochem Solutions, Inc. Method of making graft copolymers from sodium poly(aspartate) and the resulting graft copolymer
IL186598A0 (en) 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
MX2010005105A (es) 2007-11-09 2010-05-27 Allergan Inc Ciclopentanos substituidos que comprenden actividad de prostaglandina.
EP2238101A2 (de) 2008-02-05 2010-10-13 Asterand Uk Limited Difluorbiphenylamid-derivate zur behandlung von augenhochdruck
US20110152328A1 (en) 2008-04-16 2011-06-23 Whitcup Scott M Combination Therapy For Glaucoma
UA103616C2 (ru) 2008-04-24 2013-11-11 Аллерган, Инк. Замещенные гамма-лактамы как терапевтические агенты
EP2296621A1 (de) 2008-05-20 2011-03-23 Yale University Ein hydrophobes arzneimittel umfassende biologisch abbaubare polymer-mikroteilchen mit verzögerter freisetzung zur ophthalmischen anwendung
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
AU2010276648A1 (en) 2009-07-30 2012-02-23 Allergan, Inc. Selective alpha 2B/2C agonists
US20120245505A1 (en) 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
WO2011109384A2 (en) 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure

Also Published As

Publication number Publication date
ES2414183T3 (es) 2013-07-18
US7799336B2 (en) 2010-09-21
US20080131482A1 (en) 2008-06-05
WO2005110424A1 (en) 2005-11-24
EP1944032A2 (de) 2008-07-16
US20180207174A1 (en) 2018-07-26
JP2012121927A (ja) 2012-06-28
US20120219611A1 (en) 2012-08-30
BRPI0510311B1 (pt) 2019-06-04
DE602005007478D1 (de) 2008-07-24
US10328086B2 (en) 2019-06-25
KR20070004925A (ko) 2007-01-09
ES2304701T3 (es) 2008-10-16
BRPI0510311A (pt) 2007-10-16
CA2565053A1 (en) 2005-11-24
CN104288155A (zh) 2015-01-21
US20210196729A1 (en) 2021-07-01
US8206737B2 (en) 2012-06-26
CN1950091A (zh) 2007-04-18
CA2565053C (en) 2011-08-02
EP1740186A1 (de) 2007-01-10
EP1944032B1 (de) 2013-04-03
US20160324871A1 (en) 2016-11-10
US10864218B2 (en) 2020-12-15
EP1944032A3 (de) 2010-10-06
US20140371308A1 (en) 2014-12-18
JP2014058585A (ja) 2014-04-03
US20120238633A1 (en) 2012-09-20
US8637068B2 (en) 2014-01-28
JP2007535537A (ja) 2007-12-06
US9750751B2 (en) 2017-09-05
KR101117904B1 (ko) 2012-02-24
JP5705773B2 (ja) 2015-04-22
AU2005244203B2 (en) 2010-02-11
DK1944032T3 (da) 2013-06-24
US20150099805A1 (en) 2015-04-09
AU2005244203A1 (en) 2005-11-24
JP5576018B2 (ja) 2014-08-20
US9393223B2 (en) 2016-07-19
DK1740186T3 (da) 2008-10-06
NZ549516A (en) 2011-04-29
US20080131481A1 (en) 2008-06-05
BRPI0510311B8 (pt) 2021-07-27
US8206736B2 (en) 2012-06-26
US20190307769A1 (en) 2019-10-10
EP1740186B1 (de) 2008-06-11
US8900622B1 (en) 2014-12-02
US8911767B2 (en) 2014-12-16
US20050244464A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
ATE397934T1 (de) Biologisch abbaubare intraokulare implantate mit prostamiden
GB0808120D0 (en) Copolymer and polymer light emitting devices made by using the same
WO2006089267A3 (en) Synthetic structure for soft tissue repair
EP1585462A4 (de) Intraokulare implantate
DE602006009443D1 (de) Intraokulares Implantat mit komprimierbaren Haptiken
EP1809207A4 (de) Künstliches hornhautimplantat
DE602005003957D1 (de) Mit doppelextrusionsverfahren hergestelltes augenimplantat
ATE531374T1 (de) Vorrichtung auf polymerbasis mit verzögerter freisetzung
DE60205772D1 (de) Verbundbahnen mit diskreten elastischen polymerbereichen
DE60333731D1 (de) Harnröhrenstent
DK1735027T3 (da) Stabiliserede, biologisk nedbrydelige neurotoksinimplantater
DE60308410D1 (de) Bioabbaubare Polymerzusammensetzung, Füllstoff hierfür und daraus hergestelltes Formteil
DE602005020054D1 (de) Ophthalmische zusammensetzungen mit polyethersubstituierten polymeren
ATE419904T1 (de) Mundpflegezusammensetzung mit vernetztem polymerperoxid
DK1799748T3 (da) Bionedbrydelige kationiske polymerer
EP1968493A4 (de) Diffusionsgehärtetes medizinisches implantat
GB2437213B (en) Polymer compound and polymer light emitting device using the same
EP1760098A4 (de) Biokompatibles material
GB2443774B (en) Polymer compound and polymer light emitting device using the same
BRPI0611969B8 (pt) materiais e dispositivo otorrinolaringológico e oftálmico, e lente intraocular
BRPI0513872A (pt) composição polimérica, e, artigo conformado
FI20041641L (fi) Sovitelma silmänpainemittarissa
FR2854801B1 (fr) Implant injectable de globine insoluble
FR2849590B1 (fr) Implant rachidien a crochets
ATE458507T1 (de) Implantat mit mehrfachbeschichtung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1740186

Country of ref document: EP